NLNicola Logan

Nicola Logan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicola Logan has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses

    by Ryan M. Imrie, Laura A. Bissett, Savitha Raveendran, Maria Manali, Julien A. R. Amat, Laura Mojsiejczuk, Nicola Logan, Andrew Park, Marc Baguelin, Mafalda Viana, et al.

    Infections by endemic viruses, and the vaccines used to control them, often provide cross-protection against related viruses, potentially altering the transmission dynamics and likelihood of emergence of new zoonotic viruses with pandemic potential. Here, we investigate how population immunity after the COVID-19 pandemic has impacted the likelihood of emergence of a novel sarbecovirus, termed SARS-CoV-X. To this end, we combined empirical cross-neutralisation data with mathematical modelling to identify key immunological and epidemiological factors shaping sarbecovirus emergence. We show that sera from individuals with different COVID-19 immunological histories contained cross-neutralising antibodies against the spike (S) protein of multiple zoonotic sarbecoviruses. Simulations parameterised by these data predict that the likelihood of emergence of a novel sarbecovirus has been reduced significantly by population cross-immunity, with outcomes determined by the extent of cross-protection and R0 of the novel virus. Preventative vaccination against SARS-CoV-X using available COVID-19 vaccines can help resist emergence even in the presence of co-circulating SARS-CoV-2. However, a theoretical vaccine with high specificity to SARS-CoV-2 can increase emergence probability by suppressing SARS-CoV-2 prevalence and, by extension, levels of natural cross-protection. Overall, SARS-CoV-2 circulation and vaccination have generated widespread immunity against related sarbecoviruses, creating an immunological barrier to novel sarbecovirus emergence in humans.


  • Open Access

    SARS-CoV-2Infection Following Booster Vaccination: Prevalence, Immunological and Proteomic Correlates, Symptom Profiles and Household Transmission in a Longitudinal Healthcare Worker Cohort (BE-DIRECT) ​

    by Daniel Pan, Christopher Andrew Martin, Joshua Nazareth, Mrinal Das, Dan Lane, Nicola Logan, Sam Scott, Luke Bryant, Nisha George, Marjan Gohar, et al.

    Background: Healthcare workers (HCWs) remain frequently exposed to SARS-CoV-2. We aimed to quantify infection in HCWs following booster vaccination and identify immunological correlates of protection.Methods: We analysed BE-DIRECT, a longitudinal immunology cohort of UK HCWs receiving SARS-CoV-2 booster vaccinations across two booster seasons. Participants attended pre-booster (median 1 day prior to booster), post-booster (approximately 2-3 weeks) and follow-up (6-9 months) appointments. Outcome was evidence of infection by follow-up, asymptomatic infection and household transmission. Sensitivity analyses included neutralising antibody responses and plasma proteomic signatures.Findings: We included 430 HCWs in 2021-2022 and 180 in 2022-2023. Breakthrough infection was common in both years (241/430, 56% and 75/180, 42% respectively) with no reported hospitalisations. One quarter (68/241, 28%) in 2021-2022 were asymptomatic. Higher pre-booster quantitative anti-spike titres were associated with lower risk of infection in both years (aOR 0.35, 95%CI 0.21 – 0.60 per 10-fold increase in 2021-2022) and hybrid immunity with a higher risk of asymptomatic infection (aOR 2.69, 95%CI 1.47 – 4.90). Among 115 respondents, 40 (35%) reported household transmission; hybrid immunity was associated with lower transmission risk. Higher pre-boost anti-S neutralising titres in the 2021-2022 cohort was also associated with lower risk of infection (aOR:0.55, 95% CI:0.37-0.82). Proteomics identified differential abundance of proteins spanning immunoglobulin variable regions in those who developed subsequent infection.​Interpretation: SARS-CoV-2 infection remained frequent among HCWs and was often clinically silent. Hybrid immunity was associated with more favourable clinical outcomes and reduced household transmission; pre-booster anti-spike titres provided a consistent, scalable correlate of protection against infection in HCWs.

  • Open Access

    Post-pandemic changes in population immunity have reduced the likelihood of emergence of zoonotic coronaviruses

    by Ryan M Imrie, Laura A Bissett, Savitha Raveendran, Maria Manali, Julien A R Amat, Laura Mojsiejczuk, Nicola Logan, Andrew Park, Marc Baguelin, Mafalda Viana, et al.

    Infections caused by endemic viruses, and the vaccines used to control them, often provide cross-protection against related viruses. This cross-protection has the potential to alter the transmission dynamics and likelihood of emergence of novel zoonotic viruses with pandemic potential. Here, we investigate how changes in population immunity after the COVID-19 pandemic have impacted the likelihood of emergence of a novel sarbecovirus, termed SARS-CoV-X. We show that sera from patients with different COVID-19 immunological histories possess cross-neutralising antibodies against the spike (S) protein of multiple zoonotic sarbecoviruses. Mathematical simulations using these viruses show a significant reduction in their likelihood of emergence in populations with current levels of SARS-CoV-2 natural and vaccine-derived immunity, with the outcome determined by the extent of cross-protection and the R 0 of the novel virus. We also show that preventative vaccination programs against SARS-CoV-X using currently available COVID-19 vaccines can help resist emergence even in the presence of co-circulating SARS-CoV-2. However, it was possible for a theoretical vaccine with very high specificity to SARS-CoV-2 (i.e., one which elicits very low cross-protection against SARS-CoV-X) to increase the likelihood of SARS-CoV-X emergence, due to its effects on SARS-CoV-2 prevalence and, by extension, the levels of naturally-derived cross-protection in the human population. Overall, our findings show that SARS-CoV-2 circulation and COVID-19 vaccination have generated widespread population immunity against antigenically related sarbecoviruses, and this new immunological barrier is likely to be a strong determinant of the ability of novel sarbecoviruses to emerge in humans. One-Sentence Summary: Future emergence of zoonotic coronaviruses is less likely due to post-pandemic shifts in population immunity.

  • Open Access

    Omicron BA.2.86 cross-neutralising activity in community sera from the UK

    by Brian J Willett, Nicola Logan, Sam Scott, Chris Davis, Therese McSorley, Patawee Asamaphan, Margaret J Hosie, Paula Olmo, Joe Grove, Richard Orton, et al.


  • Open Access

    Rising SARS-CoV-2 Seroprevalence and Patterns of Cross-Variant Antibody Neutralization in UK Domestic Cats

    by Grace B Tyson, Sarah Jones, Nicola Logan, Michael McDonald, Pablo R Murcia, Brian J Willett, William Weir, Margaret J Hosie

    Recent evidence confirming cat-to-human SARS-CoV-2 transmission has highlighted the importance of monitoring infection in domestic cats. Although the effects of SARS-CoV-2 infection on feline health are poorly characterized, cats have close contact with humans, and with both domesticated and wild animals. Accordingly, they could act as a reservoir of infection, an intermediate host and a source of novel variants. To investigate the spread of the virus in the cat population, serum samples were tested for SARS-CoV-2 antibodies by ELISA and a pseudotype-based virus neutralization assay, designed to detect exposure to variants known to be circulating in the human population. Overall seroprevalence was 3.2%, peaking at 5.3% in autumn 2021. Variant-specific neutralizing antibody responses were detected with titers waning over time. The variant-specific response in the feline population correlated with and trailed the variants circulating in the human population, indicating multiple ongoing human-to-cat spill-over events.


  • Open Access

    Modulation of the virus-receptor interaction by mutations in the V5 loop of feline immunodeficiency virus (FIV) following in vivoescape from neutralising antibody

    by Brian J Willett, Martin Kraase, Nicola Logan, Elizabeth L McMonagle, Ayman Samman, Margaret J Hosie

    In the acute phase of infection with feline immunodeficiency virus (FIV), the virus targets activated CD4+ T cells by utilising CD134 (OX40) as a primary attachment receptor and CXCR4 as a co-receptor. The nature of the virus-receptor interaction varies between isolates; strains such as GL8 and CPGammer recognise a "complex" determinant on CD134 formed by cysteine-rich domains (CRDs) 1 and 2 of the molecule while strains such as PPR and B2542 require a more "simple" determinant comprising CRD1 only for infection. These differences in receptor recognition manifest as variations in sensitivity to receptor antagonists. In this study, we ask whether the nature of the virus-receptor interaction evolves in vivo.


  • Open Access

    A single site for N-linked glycosylation in the envelope glycoprotein of feline immunodeficiency virus modulates the virus-receptor interaction

    by Brian J Willett, Elizabeth L McMonagle, Nicola Logan, Ayman Samman, Margaret J Hosie

    Feline immunodeficiency virus (FIV) targets helper T cells by attachment of the envelope glycoprotein (Env) to CD134, a subsequent interaction with CXCR4 then facilitating the process of viral entry. As the CXCR4 binding site is not exposed until CD134-binding has occurred then the virus is protected from neutralising antibodies targeting the CXCR4-binding site on Env. Prototypic FIV vaccines based on the FL4 strain of FIV contain a cell culture-adapted strain of FIV Petaluma, a CD134-independent strain of FIV that interacts directly with CXCR4. In addition to a characteristic increase in charge in the V3 loop homologue of FIVFL4, we identified two mutations in potential sites for N-linked glycosylation in the region of FIV Env analogous to the V1–V2 region of HIV and SIV Env, T271I and N342Y. When these mutations were introduced into the primary GL8 and CPG41 strains of FIV, the T271I mutation was found to alter the nature of the virus-CD134 interaction; primary viruses carrying the T271I mutation no longer required determinants in cysteine-rich domain (CRD) 2 of CD134 for viral entry. The T271I mutation did not confer CD134-independent infection upon GL8 or CPG41, nor did it increase the affinity of the CXCR4 interaction, suggesting that the principal effect was targeted at reducing the complexity of the Env-CD134 interaction.